Activation	activation	O	O	O	O
of	of	O	O	O	O
poly(ADP-ribose	poly(adp-ribose	O	O	O	O
)	)	O	O	O	O
polymerase	polymerase	O	O	O	O
contributes	contributes	O	O	O	O
to	to	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
doxorubicin-induced	doxorubicin-induced	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Activation	activation	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
nuclear	nuclear	O	O	O	O
enzyme	enzyme	O	O	O	O
poly(ADP-ribose	poly(adp-ribose	O	O	O	O
)	)	O	O	O	O
polymerase	polymerase	O	O	O	O
(	(	O	O	O	O
PARP	parp	O	O	O	O
)	)	O	O	O	O
by	by	O	O	O	O
oxidant-mediated	oxidant-mediated	O	O	O	O
DNA	dna	O	O	O	O
damage	damage	O	O	O	O
is	is	O	O	O	O
an	an	O	O	O	O
important	important	O	O	O	O
pathway	pathway	O	O	O	O
of	of	O	O	O	O
cell	cell	O	O	O	O
dysfunction	dysfunction	O	O	O	O
and	and	O	O	O	O
tissue	tissue	O	O	OTHERS	I
injury	injury	O	O	OTHERS	I
in	in	O	O	O	O
conditions	conditions	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
oxidative	oxidative	O	O	O	O
stress	stress	O	O	O	O
.	.	O	O	O	O

Increased	increased	O	O	O	O
oxidative	oxidative	O	O	O	O
stress	stress	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
factor	factor	O	O	O	O
implicated	implicated	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
DOX	dox	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
widely	widely	O	O	O	O
used	used	O	O	O	O
antitumor	antitumor	O	O	O	O
anthracycline	anthracycline	CHEMICALS	O	OTHERS	I
antibiotic	antibiotic	O	O	O	O
.	.	O	O	O	O

Thus	thus	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
hypothesized	hypothesized	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
activation	activation	O	O	O	O
of	of	O	O	O	O
PARP	parp	O	O	O	O
may	may	O	O	O	O
contribute	contribute	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
DOX-induced	dox-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Using	using	O	O	O	O
a	a	O	O	O	O
dual	dual	O	O	O	O
approach	approach	O	O	O	O
of	of	O	O	O	O
PARP-1	parp-1	O	O	O	O
suppression	suppression	O	O	O	O
,	,	O	O	O	O
by	by	O	O	O	O
genetic	genetic	O	O	O	O
deletion	deletion	O	O	O	O
or	or	O	O	O	O
pharmacological	pharmacological	O	O	O	O
inhibition	inhibition	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
phenanthridinone	phenanthridinone	O	O	O	O
PARP	parp	O	O	O	O
inhibitor	inhibitor	O	O	O	O
PJ34	pj34	O	O	OTHERS	I
,	,	O	O	O	O
we	we	O	O	O	O
now	now	O	O	O	O
demonstrate	demonstrate	O	O	O	O
the	the	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
PARP	parp	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
DOX	dox	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

PARP-1+/+	parp-1+/+	O	O	O	O
and	and	O	O	O	O
PARP-1-/-	parp-1-/-	O	O	O	O
mice	mice	O	O	O	O
received	received	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
DOX	dox	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
25	25	O	O	O	O
mg/kg	mg/kg	O	O	O	O
i.p	i.p	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Five	five	O	O	O	O
days	days	O	O	O	O
after	after	O	O	O	O
DOX	dox	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
,	,	O	O	O	O
left	left	O	O	O	O
ventricular	ventricular	O	O	O	O
performance	performance	O	O	O	O
was	was	O	O	O	O
significantly	significantly	O	O	O	O
depressed	depressed	O	DISEASE	OTHERS	I
in	in	O	O	O	O
PARP-1+/+	parp-1+/+	O	O	O	O
mice	mice	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
only	only	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
smaller	smaller	O	O	O	O
extent	extent	O	O	O	O
in	in	O	O	O	O
PARP-1-/-	parp-1-/-	O	O	O	O
ones	ones	O	O	O	O
.	.	O	O	O	O

Similar	similar	O	O	O	O
experiments	experiments	O	O	O	O
were	were	O	O	O	O
conducted	conducted	O	O	O	O
in	in	O	O	O	O
BALB/c	balb/c	O	O	O	O
mice	mice	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
PJ34	pj34	O	O	OTHERS	I
or	or	O	O	O	O
vehicle	vehicle	O	O	O	O
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
PJ34	pj34	O	O	OTHERS	I
significantly	significantly	O	O	O	O
improved	improved	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
dysfunction	dysfunction	O	DISEASE	OTHERS	I
and	and	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
survival	survival	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
animals	animals	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
PJ34	pj34	O	O	OTHERS	I
significantly	significantly	O	O	O	O
reduced	reduced	O	O	O	O
the	the	O	O	O	O
DOX-induced	dox-induced	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
serum	serum	O	O	O	O
lactate	lactate	CHEMICALS	O	OTHERS	I
dehydrogenase	dehydrogenase	O	O	O	O
and	and	O	O	O	O
creatine	creatine	CHEMICALS	O	OTHERS	I
kinase	kinase	CHEMICALS	O	OTHERS	I
activities	activities	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
metalloproteinase	metalloproteinase	O	O	O	O
activation	activation	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
heart	heart	O	O	O	O
.	.	O	O	O	O

Thus	thus	O	O	O	O
,	,	O	O	O	O
PARP	parp	O	O	O	O
activation	activation	O	O	O	O
contributes	contributes	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
DOX	dox	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

PARP	parp	O	O	O	O
inhibitors	inhibitors	O	O	O	O
may	may	O	O	O	O
exert	exert	O	O	O	O
protective	protective	O	O	O	O
effects	effects	O	O	O	O
against	against	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
severe	severe	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
complications	complications	O	O	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
DOX	dox	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

